255 related articles for article (PubMed ID: 30827127)
1. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
3. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Fruehauf S; Otremba B; Stötzer O; Rudolph C
Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
6. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
Aapro M; Ludwig H; Bokemeyer C; Gascón P; Boccadoro M; Denhaerynck K; Krendyukov A; Gorray M; MacDonald K; Abraham I
Ann Oncol; 2016 Nov; 27(11):2039-2045. PubMed ID: 27793849
[TBL] [Abstract][Full Text] [Related]
7. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
10. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Gascón P; Krendyukov A; Höbel N; Aapro M
Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
[TBL] [Abstract][Full Text] [Related]
11. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Bokemeyer C; Gascón P; Aapro M; Ludwig H; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; Abraham I; MacDonald K
Support Care Cancer; 2017 Jun; 25(6):1819-1828. PubMed ID: 28111718
[TBL] [Abstract][Full Text] [Related]
12. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
Aapro M; Krendyukov A; Höbel N; Gascon P
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13034. PubMed ID: 30968997
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
16. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
Trautman H; Szabo E; James E; Tang B
J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
[TBL] [Abstract][Full Text] [Related]
17. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
[No Abstract] [Full Text] [Related]
18. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
